206 related articles for article (PubMed ID: 27550238)
1. Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Ueda H; Hayashi H; Kudo K; Takeda M; Nakagawa K
Invest New Drugs; 2016 Dec; 34(6):797-799. PubMed ID: 27550238
[TBL] [Abstract][Full Text] [Related]
2. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
3. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.
Zenke Y; Umemura S; Sugiyama E; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Goto K
Lung Cancer; 2016 Sep; 99():1-3. PubMed ID: 27565905
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Fujiwara A; Yoshida M; Fujimoto H; Nakahara H; Ito K; Nishihama K; Yasuma T; Hataji O; Taguchi O; D'Alessandro-Gabazza CN; Gabazza EC; Kobayashi T
Oncol Res; 2018 Aug; 26(7):1031-1036. PubMed ID: 29321093
[TBL] [Abstract][Full Text] [Related]
7. Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Toba H; Sakiyama S; Takizawa H; Tangoku A
J Med Invest; 2016; 63(1-2):149-51. PubMed ID: 27040072
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Burotto M; Manasanch EE; Wilkerson J; Fojo T
Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
[TBL] [Abstract][Full Text] [Related]
9. Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Tamiya M; Shiroyama T; Nishihara T; Nishida T; Hayama M; Tanaka A; Morishita N; Suzuki H; Okamoto N; Hirashima T
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e531-e533. PubMed ID: 28004883
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
[TBL] [Abstract][Full Text] [Related]
14. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
15. Afatinib and lung cancer.
Jain P; Khanal R; Sharma A; Yan F; Sharma N
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1391-406. PubMed ID: 25417728
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients: A network meta-analysis.
Wu Z; Chen S; Du X; Wu Y; Xie X
J Clin Pharm Ther; 2021 Apr; 46(2):310-318. PubMed ID: 33031574
[TBL] [Abstract][Full Text] [Related]
17. [Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report].
Durand M; Logerot S; Fonrose X; Schir E
Therapie; 2014; 69(2):163-8. PubMed ID: 24926635
[TBL] [Abstract][Full Text] [Related]
18. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.
Köhler J; Schuler M
Onkologie; 2013; 36(9):510-8. PubMed ID: 24051929
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.
Kunimasa K; Yoshioka H; Iwasaku M; Nishiyama A; Korogi Y; Masuda G; Takaiwa T; Ishida T
Intern Med; 2012; 51(4):431-4. PubMed ID: 22333382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
